×
About 90,480 results

ALLMedicine™ Coronary Artery Disease Center

Research & Reviews  43,345 results

Genome-Wide Polygenic Score, Clinical Risk Factors, and Long-Term Trajectories of Coron...
https://doi.org/10.1161/ATVBAHA.120.314856
Arteriosclerosis, Thrombosis, and Vascular Biology; Hindy G, Aragam KG et. al.

Sep 22nd, 2020 - To determine the relationship of a genome-wide polygenic score for coronary artery disease (GPSCAD) with lifetime trajectories of CAD risk, directly compare its predictive capacity to traditional risk factors, and assess its interplay with the Poo...

Effect of Shexiang Tongxin dropping pill on stable coronary artery disease patients wit...
https://doi.org/10.1097/MD.0000000000022126
Medicine Lu Y, Chu X et. al.

Sep 22nd, 2020 - Coronary microvascular disease (CMVD) can affect the structure, function, and metabolism of the heart, and has an important impact on the occurrence, development and prognosis of coronary artery disease (CAD). Shexiang Tongxin dropping pill (STDP)...

Incremental prognostic value of hybrid 15OH2O positron emission tomography-computed tom...
https://doi.org/10.1093/ehjci/jeaa192
European Heart Journal Cardiovascular Imaging; Driessen RS, Bom MJ et. al.

Sep 22nd, 2020 - This study sought to determine the prognostic value of combined functional testing using positron emission tomography (PET) perfusion imaging and anatomical testing using coronary computed tomography angiography (CCTA)-derived stenosis severity an...

Ticagrelor in the management of coronary artery disease.
https://doi.org/10.2217/fca-2020-0108
Future Cardiology; Loganath K, Adamson PD et. al.

Sep 22nd, 2020 - Ticagrelor is a potent and orally active P2Y12 inhibitor. Ticagrelor has been extensively tested in Phase II and Phase III trials in patients with coronary artery disease. The pharmacokinetics and pharmacodynamics of Ticagrelor result in more rapi...

Cardiometabolic Risk Factors and Coronary Artery Disease in Women.
https://doi.org/10.1089/jwh.2020.8755
Journal of Women's Health (2002); Lønnebakken MT

Sep 22nd, 2020 - Cardiometabolic Risk Factors and Coronary Artery Disease in Women.|2020|Lønnebakken MT,|

see more →

Guidelines  127 results

ACR Appropriateness Criteria® Chest Pain-Possible Acute Coronary Syndrome.
https://doi.org/10.1016/j.jacr.2020.01.027
Journal of the American College of Radiology : JACR; , Batlle JC et. al.

May 5th, 2020 - Chest pain is a frequent cause for emergency department visits and inpatient evaluation, with particular concern for acute coronary syndrome as an etiology, since cardiovascular disease is the leading cause of death in the United States. Although ...

The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics
https://www.sciencedirect.com/science/article/abs/pii/S0002870319302698?via%3Dihub
American Heart Journal; Nidorf SM,et al

Nov 30th, 2019 - Because patients with stable coronary artery disease are at continued risk of major atherosclerotic events despite effective secondary prevention strategies, there is a need to continue to develop additional safe, effective and well-tolerated ther...

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa1909406

Sep 27th, 2019 - BACKGROUND Long-term outcomes after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents, as compared with coronary-artery bypass grafting (CABG), in patients with left main coronary artery disease are not clearly establi...

Lipoprotein(a): The Next Promising CVD Risk Assessment Tool and Prevention Target Among the High-risk Population
https://www.acc.org/latest-in-cardiology/articles/2019/09/17/15/02/lipoprotein-a

Sep 17th, 2019 - After low density lipoprotein cholesterol (LDL-C) has been targeted to reduce cardiovascular disease (CVD) risk, other novel lipid biomarkers have become the center of attention of investigation, and on-going clinical trials are targeting these li...

HeartFlow Announces FDA Clearance for HeartFlow Planner
https://www.heartflow.com/newsroom/heartflow-announces-fda-clearance-for-heartflow-planner

Sep 11th, 2019 - HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention. The HeartFlo...

see more →

Drugs  699 results see all →

Clinicaltrials.gov  44,753 results

Genome-Wide Polygenic Score, Clinical Risk Factors, and Long-Term Trajectories of Coron...
https://doi.org/10.1161/ATVBAHA.120.314856
Arteriosclerosis, Thrombosis, and Vascular Biology; Hindy G, Aragam KG et. al.

Sep 22nd, 2020 - To determine the relationship of a genome-wide polygenic score for coronary artery disease (GPSCAD) with lifetime trajectories of CAD risk, directly compare its predictive capacity to traditional risk factors, and assess its interplay with the Poo...

Effect of Shexiang Tongxin dropping pill on stable coronary artery disease patients wit...
https://doi.org/10.1097/MD.0000000000022126
Medicine Lu Y, Chu X et. al.

Sep 22nd, 2020 - Coronary microvascular disease (CMVD) can affect the structure, function, and metabolism of the heart, and has an important impact on the occurrence, development and prognosis of coronary artery disease (CAD). Shexiang Tongxin dropping pill (STDP)...

Incremental prognostic value of hybrid 15OH2O positron emission tomography-computed tom...
https://doi.org/10.1093/ehjci/jeaa192
European Heart Journal Cardiovascular Imaging; Driessen RS, Bom MJ et. al.

Sep 22nd, 2020 - This study sought to determine the prognostic value of combined functional testing using positron emission tomography (PET) perfusion imaging and anatomical testing using coronary computed tomography angiography (CCTA)-derived stenosis severity an...

Ticagrelor in the management of coronary artery disease.
https://doi.org/10.2217/fca-2020-0108
Future Cardiology; Loganath K, Adamson PD et. al.

Sep 22nd, 2020 - Ticagrelor is a potent and orally active P2Y12 inhibitor. Ticagrelor has been extensively tested in Phase II and Phase III trials in patients with coronary artery disease. The pharmacokinetics and pharmacodynamics of Ticagrelor result in more rapi...

Cardiometabolic Risk Factors and Coronary Artery Disease in Women.
https://doi.org/10.1089/jwh.2020.8755
Journal of Women's Health (2002); Lønnebakken MT

Sep 22nd, 2020 - Cardiometabolic Risk Factors and Coronary Artery Disease in Women.|2020|Lønnebakken MT,|

see more →

News  1,469 results

AstraZeneca's heart drug gets FDA nod
https://www.reuters.com/article/us-astrazeneca-fda/astrazenecas-heart-drug-gets-fda-nod-idUSKBN2381FJ

Jun 1st, 2020 - FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble (Reuters) - AstraZeneca Plc said on Monday the U.S. Food and Drug Administration has approved its drug for reducing the ri...

A Case-Based Review of Iron Overload With an Emphasis on Porphyria Cutanea Tarda, Hepatitis C, C282Y Heterozygosity, and Coronary Artery Disease
https://www.mdedge.com/fedprac/article/216484/hepatitis/case-based-review-iron-overload-emphasis-porphyria-cutanea-tarda/page/0/4?channel=314

Jan 31st, 2020 - Iron Overload and Cardiovascular Risk In 1987, a Framingham cohort of > 2,800 patients showed a higher incident of CAD in postmenopausal women when compared with premenopausal women. 12 In the 1980s, Sullivan hypothesized that the reason for higher.

Why STEMI patients benefit from PCI of nonculprit lesions
https://www.mdedge.com/jcomjournal/article/215900/cardiology/why-stemi-patients-benefit-pci-nonculprit-lesions?channel=194
Bruce Jancin

Jan 22nd, 2020 - PHILADELPHIA – Nearly half of patients with ST-elevation MI and multivessel coronary artery disease in the landmark COMPLETE trial had an obstructive coronary lesion with vulnerable plaque morphology in a segment far from the culprit lesion, Natal.

The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics
https://www.sciencedirect.com/science/article/abs/pii/S0002870319302698?via%3Dihub
American Heart Journal; Nidorf SM,et al

Nov 30th, 2019 - Because patients with stable coronary artery disease are at continued risk of major atherosclerotic events despite effective secondary prevention strategies, there is a need to continue to develop additional safe, effective and well-tolerated ther...

Stress echo could predict PCI efficacy in stable CAD
https://www.mdedge.com/cardiology/article/212446/cad-atherosclerosis/stress-echo-could-predict-pci-efficacy-stable-cad?channel=39313
Bianca Nogrady

Nov 16th, 2019 - Dobutamine stress echocardiography could be used to predict which patients with single-vessel stable coronary artery disease are most likely to benefit from percutaneous coronary intervention, according to secondary analysis of data from the ORBIT.

see more →

Patient Education  87 results see all →